Clinical Trials Logo

IBS - Irritable Bowel Syndrome clinical trials

View clinical trials related to IBS - Irritable Bowel Syndrome.

Filter by:

NCT ID: NCT05205785 Recruiting - Clinical trials for Irritable Bowel Syndrome

Human Milk Oligosaccharides (HMOs) for Irritable Bowel Syndrome (IBS)

HIBS
Start date: March 22, 2023
Phase: N/A
Study type: Interventional

To assess the effects of a Human Milk Oligosaccharide mix given once daily for 12 weeks on stool consistency and abdominal pain compared to placebo in individuals with Irritable Bowel Syndrome (IBS).

NCT ID: NCT05197413 Completed - Anxiety Clinical Trials

Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

This is an open-label observational crossover trial to study the efficacy of a commercial dietary supplement and its effect on common symptoms of IBS (such as bloating, gas, heartburn, and other symptoms).

NCT ID: NCT05192603 Enrolling by invitation - Clinical trials for IBS - Irritable Bowel Syndrome

Comparison Between Low FODMAP and SSRD in IBS

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

The aim of the present study is to compare the efficiency of low FODMAP and SSRD to reduce symptoms in IBS, and to study the mechanisms and consequences of the two diets.

NCT ID: NCT05178017 Recruiting - Clinical trials for IBS - Irritable Bowel Syndrome

Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory eating plan guided by a registered dietitian to treat irritable bowel syndrome.

NCT ID: NCT05155631 Recruiting - Clinical trials for IBS - Irritable Bowel Syndrome

Sex Differences in Effectiveness of CBT on IBS Project 3

U54_P3_CBT
Start date: December 18, 2021
Phase: N/A
Study type: Interventional

Cognitive Behavioral Therapy (CBT) is the most well researched and most effective treatment for IBS targeting the brain-gut-microbiome (BGM) axis, and preliminary data show that this therapeutic effect is associated with a reduction of brainstem connectivity with other brain networks. The increased prevalence of IBS in women, the higher rate of comorbid non-GI pain conditions, as well as the higher prevalence in female IBS of increased sensitivity to a variety of internal and external stimuli (multisensory sensitivity) suggest the presence of important sex differences in some of these BGM mechanisms. Research performed by UCLA SCOR during previous funding has established an increased responsiveness of the CRF-Locus Coeruleus (LCC) system in female IBS subjects, suggesting that this central noradrenergic brainstem system plays an important role in IBS pathophysiology. In addition, the study team's earlier research has begun to identify clinical, functional and structural brain mechanisms that may underlie these sex effects. Based on the preliminary data, the overall goal of this project is to use CBT as a probe to study the relationship between specific disease-related alterations of the brain, the gut microbiome, and symptomatic outcome, and identify the role of sex differences in these relationships. Investigators will study male and female IBS patients before and after CBT using the advanced neuroimaging and microbiome technologies of the overall SCOR.

NCT ID: NCT05118243 Active, not recruiting - Clinical trials for IBS - Irritable Bowel Syndrome

Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance

LeguComf
Start date: September 6, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the effects of enzymatic treatment to reduce GOS (galactooligosaccharides) in legume-based crackers in IBS (irritable bowel syndrome) persons. The crackers are pea-based: the control crackers contain high amounts of GOS, while the enzymatically treated crackers contain a minimal amount of GOS. The participants will eat each type of cracker for three days (daily dose of 12 crackers) and report their gut symptoms (e.g. flatulence, stomach pain, bloating) by using a mobile app. There is a washout period of four days between the different crackers. In addition, the participants will keep food records on the cracker eating days as well as collect five fecal samples during the study. The participants will also report their physical activity and the number of defecations on each day. The study is carried out in a double-blinded crossover setting.

NCT ID: NCT05054309 Recruiting - Clinical trials for IBS - Irritable Bowel Syndrome

A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome

Mood-01
Start date: February 11, 2022
Phase: N/A
Study type: Interventional

This is a prospective, randomized, placebo-controlled, double-blind, multi-center parallel- design study to evaluate the effect of BL NCC3001 in subjects with Irritable Bowel Syndrome.

NCT ID: NCT05016596 Completed - Clinical trials for IBS - Irritable Bowel Syndrome

Postprandial Lipids in IBS and Nutritional Treatment

PLINT
Start date: November 15, 2021
Phase: N/A
Study type: Interventional

Irritable Bowel Syndrome (IBS) is a disease that affects a large number of people. Adequate treatment is difficult, partially due to the heterogeneity of the patients and the complicated pathology in which not all mechanisms are understood. Based on literature and in vitro screening within the public private IBSQUtrition consortium project, a turmeric supplement was selected for in vivo validation of its potential beneficial effects on fat-induced intestinal barrier disruption as measured with LPS translocation in IBS patients with a diarrhea-predominant subtype (IBS-D). The primary objective of this study is to determine the effect of turmeric supplementation on LPS translocation in IBS-D patients after a high-fat challenge. The secondary objective of this study is to determine the effect of turmeric supplementation on gastrointestinal complaints and LPS-related biomarkers in IBS-D patients after a high-fat challenge. In this double-blind, randomized, placebo-controlled cross-over trial 20 adult (18-70 yrs) IBS-D patients will be included. Study participants have to invest about 16 hours of their time in this study. They will visit the research facility three times. The risks for participation are very small if not negligible. Consumption of high amounts of saturated fat may cause some gastro-intestinal discomfort. Blood sampling will be performed via a cannula and the insertion can be a bit painful and may cause a bruise. The amount of blood that is drawn from participants is relatively small and within acceptable limits.

NCT ID: NCT04946604 Completed - Clinical trials for IBS - Irritable Bowel Syndrome

Ashtangayoga for IBS Show Positive Preliminary Effects on Symptoms and Well-being

Start date: January 18, 2018
Phase: N/A
Study type: Interventional

The study aims to test the effect of Ashtanga yoga on well-being in patients with irritable bowel syndrome (IBS). The intervention comprises group sessions on the Ashtanga school of yoga. Participants are recruited from primary care and measurements on well-being and IBS symptoms are conducted at pre-treatment, post-treatment and 6-month follow-up.

NCT ID: NCT04905524 Completed - Depression, Anxiety Clinical Trials

Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Viome costumers are consented and recruited for this study and complete the questionnaires upon enrollment. Any participant who previously self reported depression, anxiety, or Irritable Bowel Syndrome (IBS) qualify for this study. All participants receive Viome's diet, supplement and recommendations.